Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer - Slideshow

What happened: Zai Lab Limited ($ZLAB) published a slide deck in connection with an event discussing Phase 1 study results of its DLL3-targeted ADC ZL-1310 in small cell lung cancer. Why it matters: The slideshow accompanies the company's presentation of Phase 1 data for ZL-1310, a DLL3-targeted antibody-drug conjugate being studied in small cell lung cancer.

Zai Lab Limited ($ZLAB) published a slide deck in connection with an event discussing Phase 1 study results of its DLL3-targeted ADC ZL-1310 in small cell lung cancer.

The slideshow accompanies the company's presentation of Phase 1 data for ZL-1310, a DLL3-targeted antibody-drug conjugate being studied in small cell lung cancer.